Vitala, member of CataloniaBio & HealthTech, is one of the three Catalan startups to be among the first to access ACCIÓ Startup Capital co-investment line for 'deeptech' startups, launched in 2023 with a total budget of 2.5 million euros. 

MiMARK Diagnostics, member of CataloniaBio & HealthTech, has successfully raised a total of 1.2 million euros for an innovative project focused on the diagnosis of endometrial cancer. 

CataloniaBio & HealthTech was a special guest at the second edition of the Foro BIO 2023, held this 11 October in Cordoba, Argentina. Javier Selva, CEO of CataloniaBio & HealthTech, participated with a conference focused on competitiveness policies, to explain the health ecosystem in Catalonia and the strengths of the 30 years of cluster policy in Catalonia.

SpliceBio, una empresa de teràpia gènica que utilitza l’splicing de proteïnes per desenvolupar la propera generació de teràpies genètiques, ha anunciat la signatura d’un acord exclusiu de col·laboració i llicència amb Spark Therapeutics per utilitzar la plataforma d’splicing de proteïnes propietat d’SpliceBio amb la finalitat de desenvolupar una teràpia gènica per una malaltia hereditària de la retina no revelada. SpliceBio és membre de CataloniaBio & HealthTech.

Oncoheroes Biosciences, membre de CataloniaBio & HealthTech, ha anunciat que l'Administració d'Aliments i Medicaments (FDA) dels Estats Units ha concedit la designació de medicament orfe al dovitinib pel seu ús en el tractament de l'osteosarcoma.

Una vintena de CEOs de CataloniaBio &HealthTech es van reunir el dimarts 10 d’octubre, al HUB cambraDigital (Cambra de Comerç de Barcelona), en la darrera edició del CEO Council. El convidat especial en aquesta edició ha estat Xavier Prats, actualment president del Patronat de l’Hospital de Sant Pau (Barcelona); la benvinguda i moderació de la conversa ha estat a càrrec de Joan Puig de Dou, CEO de Kymos i President de CataloniaBio & HealthTech.

Almirall, a global biopharmaceutical company focused on medical dermatology, today announced an agreement with Centrient Pharmaceuticals, a global business-to-business pioneer in sustainable, biosynthetic pharmaceutical products, including antibiotics, next-generation statins, and anti-fungals,, to open its new dedicated innovation lab at Almirall’s R&D centre. Centrient's new Innovation Laboratory will start operations in the first quarter of 2024.

Agomab Therapeutics NV today announced the closing of a $100 million Series C financing round led by Fidelity Management & Research Company (FMR), with participation from new investors EQT Life Sciences (EQT), Canaan, Kohlberg Kravis Roberts & Co (KKR Dawn) and existing investors Asabys , member of CataloniaBio & HealthTech, (through its funds Sabadell Asabys and Top Up Fund), Pfizer, Pontifax, Redmile, Cormorant, Andera Partners, AdBio and Walleye. 

OneChain Immunotherapeutics (OCI), member of CataloniaBio & HealthTech, has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA)to OC-1, a CAR T therapy against for the treatment of acute lymphoblastic leukemia (ALL), an aggressive subtype of T-cell leukemia. The company, which is part of the 1st generation of companies accelerated in the BCN Health Booster, has already started the CARxALL clinical trial to evaluate the safety and effectiveness of the product in humans. 

Aptadel Therapeutics, member of CataloniaBio & HealthTech, has named Gisela Lorente, to date the chief scientific officer, as the company’s new CEO. In this new period as CEO of Aptadel, the scientist and entrepreneur takes on the management of leading the spin-off’s strategic plan, focusing on its growth and profitability, as well as the challenge of making it a renowned company in the treatment of childhood cancer with RNA therapies. 

Amgen, member of CataloniaBio & HealthTech, has completed the acquisition of Horizon Therapeutics plc for $116.50 per action, representing a transaction value of approximately $27.8M. 

Renalyse, a CataloniaBio & HealthTech member, has concluded an investment round led by the Mind the Gap program of the Botín Foundation, with participation from GENESIS Ventures and the Eurostars program. In this manner, Renalyse has secured 1 M€ that will be allocated towards the industrialization and certification of its Chronic Kidney Disease diagnostic and monitoring device.

Onalabs Inno-Hub, the startup, a member of CataloniaBio & HealthTech, pioneer in the the development of medical devices capable of reading, measuring, and monitoring physical and biochemical physical and biochemical parameters of the skin through the sweat, has announced the successful completion of a capital increase of 1.8 million euros, thus multiplying its valuation by x2 in the short term of one year.

ADmit Therapeutics has secured a €5.4 million equity round with Clave Capital as the lead investor, with significant support from the EIC Fund and the Alzheimer's Drug Discovery Foundation (ADDF) Diagnostics Accelerator (DxA), alongside other investors such as Lavanda Ventures, Ship2B and WA4Steam. This funding round will enable the company to obtain CE marking and FDA approval for the commercialization of MAP-AD in Europe and the United States.

COMSER, a CataloniaBio & HealthTech member, highly specialized in services for the development and manufacture of lyophilized injectable drugs, announces the launch of an innovative technology to monitor product quality during the process. LyoFlow® has been developed by COMSER, within the framework of a research project initiated five years ago.

CaixaForum Macaya hosted today the debate session “UnConference 2023. Advanced therapies. An innovative market capable of improving the quality of life", organized by the organization CataloniaBio & HealthTech and in which more than 120 entrepreneurs and managers from the health sector have participated. 

Oncoheroes, member of CataloniaBio & HealthTech, announces that the US Food and Drug Administration (FDA) has allowed them to move forward with research on two of their potential paediatric oncology drugs, volasertib and dovitinib. This success reflects their unwavering commitment to pioneering therapies for children battling cancer. 

GoodGut, member of CataloniaBio & HealthTech, together with the Spanish Association of Specialists in Occupational Medicine (AEEMT) have announced a collaboration agreement to introduce digestive health as a new paradigm in occupational health.

Vytrus Biotech, member of CataloniaBio & HealthTech, has joined the Manifesto for an Economy with Purpose promoted by the organisation Respon.cat in view of the new role of companies as transforming agents and drivers of change in society and the world. 

Reig Jofre, member of CataloniaBio & HealthTech, has appointed Alex Sanfeliu as Global Head of Pharmaceutical Technologies Business Unit. He has a high responsibility in the commercial and strategic field in the pharmaceutical industry. He has worked in several countries such as the UK, France and Switzerland and has worked for international companies, including Novartis.